Acylated compounds for the treatment of ocular pathologies

Abstract

A therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration, inter alia. A method of treating and/or preventing ocular pathologies, wherein the method includes administering to a patient in need of treatment a therapeutically effective amount of a compound of general formula (I) or any of its isomers, their pharmaceutically acceptable salts, esters, tautomers, polymorphs, or hydrates.

What is claimed is: 
     
         1 . A method of treating and/or preventing ocular pathologies, wherein the method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) 
       
         
           
           
               
               
           
         
         or any of its isomers, their pharmaceutically acceptable salts, esters, tautomers, polymorphs, or hydrates, where: 
         R 1  is a C 1 -C 22  alkyl group or a C 2 -C 22  alkenyl group. 
       
     
     
         2 . The method of  claim 1 , wherein R 1  is a C 2 -C 20  alkyl group. 
     
     
         3 . The method of  claim 2 , wherein the compounds are selected from the group consisting of: trans-resveratrol-3-O-(6′-O-butanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-octanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-hexadecanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-octadecanoyl)-β-D-glucopyranoside, and any combination thereof. 
     
     
         4 . The method of  claim 3 , wherein the compound is trans-resveratrol-3-O-(6′-O-octanoyl)-β-D-glucopyranoside. 
     
     
         5 . The method of  claim 1 , wherein the pathologies are hereditary degenerative pathologies of the retina selected from among retinitis pigmentosa and pathologies within the group of retinal dystrophies selected from the group consisting of autosomal dominant retinitis pigmentosa, autosomal recessive retinitis pigmentosa, retinitis pigmentosa linked to the X chromosome, sporadic retinitis pigmentosa, retinitis pigmentosa associated with other syndromes, Cokayne syndrome, cone dystrophies, cone and rod degeneration, Leber's congenital amaurosis, retinitis  Punctata albescens , choroideremia, choroidal and retinal gyrate atrophy, choroidal generalized dystrophy, juvenile retinoschisis, Wagner's vitreoretinal degeneration, autosomal dominant vitreoretinal choroidopathy, fundus albipunctatus, Stargardt's disease, Best vitelliform macular dystrophy, Usher syndrome, Bardet-Biedl syndrome, fenestrated macular dystrophy, Sorsby pseudoinflammatory macular dystrophy, and/or dominant drusen. 
     
     
         6 . The method of  claim 1 , wherein the ocular pathologies are age-related macular degeneration. 
     
     
         7 . The method of  claim 1 , wherein the ocular pathologies are degenerative inflammatory pathologies of the retina and of the optic nerve. 
     
     
         8 . The method of  claim 1 , wherein the ocular pathologies are ocular pathologies that increase intraocular pressure and that involve degeneration of the ganglion cells of the retina and atrophy of the optic nerve selected from the group consisting of open-angle and closed-angle glaucoma. 
     
     
         9 . The method of  claim 1 , wherein the ocular pathologies are neurological pathologies that are accompanied by degenerative lesions of the retinal or optic nerve selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Graefe syndrome, Hallgren syndrome, Hallen Vorden Spatz syndrome, autosomal dominant cerebellar ataxia, and pigmentary degeneration of the retina. 
     
     
         10 . The method of  claim 1 , wherein the compound of formula (I) is administered together with a controlled-release system. 
     
     
         11 . The method of  claim 10 , wherein the controlled-release system is a cyclodextrin. 
     
     
         12 . The method of  claim 11 , wherein the cyclodextrin is 2-hydroxypropyl β-cyclodextrin. 
     
     
         13 . A pharmaceutical composition comprising at least one compound of the general formula (I): 
       
         
           
           
               
               
           
         
         or any of its isomers, their pharmaceutically acceptable salts, esters, tautomers, polymorphs, or hydrates, where: 
         R 1  is a C 1 -C 22  alkyl group or a C 2 -C 22  alkenyl group; 
         and a cyclodextrin. 
       
     
     
         14 . The composition of  claim 13 , wherein the compound of formula (I) is selected from among trans-resveratrol-3-O-(6′-O-butanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-octanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-hexadecanoyl)-β-D-glucopyranoside, trans-resveratrol-3-O-(6′-O-octadecanoyl)-β-D-glucopyranoside, and any combination thereof. 
     
     
         15 . The composition of  claim 13 , wherein the cyclodextrin is 2-hydroxypropyl β-cyclodextrin.